Healthcare

PharmaDrug (OTC: LMLLF) Advances Oncology Program with Filing of Provisional Patent Following Positive Findings for the Combination of PD-001 and Frontline Chemotherapy in Prostate Cancer Study

Provisional patent filed (April 14, 2022) to support use of PD-001 plus cabazitaxel for primary, metastatic and chemotherapy-resistant prostate cancer Final study results show that oral cepharanthine (PD-001) plus cabazitaxel combination therapy significantly reduced tumor […]

Newsmakers

Nextech AR (OTC: NEXCF) Launches Ground-Breaking Integrated SaaS Platform “Nextech Metaverse Suite”

This integration of the Company’s 3D and AR SaaS offerings in one login portal marks a major milestone with substantial SaaS revenue implications TORONTO, April 14, 2022—Nextech AR Solutions Corp. (“Nextech” or the “Company”) (OTCQB: NEXCF) […]

Newsmakers

LIXTE Biotechnology (NASDAQ: LIXT) Announces Preclinical Results of its Collaboration with the Netherlands Cancer Institute, Revealing Striking Anti-Cancer Activity of LB-100 In Novel Drug Combinations

PASADENA, CA, April 12, 2022 — LIXTE Biotechnology Holdings, Inc. (NASDAQ: LIXT), a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, announces that Professor René Bernards, Netherlands Cancer Institute (NKI), Amsterdam, presented new data […]

No Picture
Healthcare

Veru’s Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy

— Independent Data Monitoring Committee Unanimously Recommends that Phase 3 Clinical Trial for Sabizabulin for Treatment of Hospitalized COVID-19 Patients at High Risk for ARDS Be Stopped Early Due to Overwhelming Evidence of Efficacy — […]

No Picture
Healthcare

Hoth Therapeutics (NASDAQ: HOTH) mRNA Frame-Shifting Therapeutic, HT-KIT, Proves Effective Against Aggressive Cancer Cells

Treatment with HT-KIT prevented cancer cell growth and induced death in neoplastic mast cells over 72 hours HT-KIT inhibits tumor growth and systemic organ infiltration using both an allograft mastocytosis model and a humanized xenograft […]

No Picture
Aerospace & Defense

Momentus (NASDAQ: MNTS) Signs Launch Services Agreements With SpaceX

Launch reservations establish targeted flight schedule through 2023 SAN JOSE, Calif., April 07, 2022—Momentus Inc. (NASDAQ: MNTS) (“Momentus” or the “Company”), a U.S. commercial space company that plans to offer transportation and other in-space infrastructure […]

No Picture
Newsmakers

Guardforce AI (NASDAQ:GFAI) Initiates Robotics Solutions Upgrades for Hotels Through Mutual Agreement with Blue Pin

NEW YORK, NY / April 8, 2022 / Guardforce AI Co., Limited (“Guardforce AI” or the “Company”) (NASDAQ:GFAI)(NASDAQ:GFAIW), an integrated security solutions provider, today announced it has entered into a mutual agreement with Blue Pin (HK) Limited […]

No Picture
Newsmakers

Phio Pharmaceuticals (NASDAQ: PHIO) Presents Positive New Data on PH-894 Demonstrating Antitumor Efficacy in Model of PD-1 Refractory Disease at the AACR Annual Meeting 2022

MARLBOROUGH, Mass., April 8, 2022 — Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today presented positive new preclinical […]